These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22391612)

  • 1. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.
    de Kok IM; van Rosmalen J; Dillner J; Arbyn M; Sasieni P; Iftner T; van Ballegooijen M
    BMJ; 2012 Mar; 344():e670. PubMed ID: 22391612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
    van Rosmalen J; de Kok IM; van Ballegooijen M
    BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
    Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
    J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
    Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
    Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
    Goldie SJ; Kim JJ; Wright TC
    Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
    Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
    Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Computer-Assisted Cytology in a Primary hrHPV-Based Cervical Cancer Screening Programme.
    Olthof EMG; Kaljouw S; van Kemenade FJ; Uyterlinde AM; de Kok IMCM
    Cancer Med; 2024 Oct; 13(19):e70299. PubMed ID: 39400537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta.
    Campos NG; Scarinci IC; Tucker L; Peral S; Li Y; Regan MC; Sy S; Castle PE; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1114-1121. PubMed ID: 33771846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
    Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
    Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
    BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial.
    Kitchener HC; Blanks R; Cubie H; Desai M; Dunn G; Legood R; Gray A; Sadique Z; Moss S;
    Health Technol Assess; 2011 Jan; 15(3):iii-iv, ix-xi, 1-170. PubMed ID: 21266159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
    Jansen EEL; Ivanuš U; Jerman T; de Koning HJ; de Kok IMCM
    Gynecol Oncol; 2021 Jan; 160(1):118-127. PubMed ID: 33199028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.
    Maver PJ; Poljak M
    Clin Microbiol Infect; 2020 May; 26(5):579-583. PubMed ID: 31539637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
    Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
    Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
    Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
    BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.